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ABSTRACT
Introduction Antimicrobial resistance (AMR) is increasing 
in low resource settings. It complicates the management 
of infectious diseases and is an increasing cause of 
death. This is due to, among other things, lack of health 
resources for appropriate diagnosis and unregulated 
access to antimicrobials in the public sphere. Developing 
context- specific interventions that enable judicious use of 
antimicrobials is important to curb this problem.
Methods We will conduct a systematic review of 
antimicrobial stewardship (AMS) approaches in 
Development Assistance Committee in least developed 
and low- income countries. The inclusion criteria are 
antimicrobial stewardship interventions in hospitalised 
patients of all age groups and exclusion criteria are 
community- based trials and studies that solely focus 
on viral, fungal or parasite infections. Antimicrobial 
stewardship interventions will be classified as structural, 
enabling, persuasive, restrictive or combined. Outcomes 
of included studies will be classified as clinical, 
microbiological or behavioural outcomes. The studies to 
be included will be randomised controlled trials, controlled 
before–after studies, interrupted time series trials, cohort 
and qualitative studies. Data will be extracted using forms 
adapted from the Cochrane collaboration data collection 
form. This systematic review will be conducted according 
to the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses guidelines and risk of bias will be done 
according to the Integrated quality Criteria for Review of 
Multiple Study Designs.
Ethics and dissemination Our findings will be presented 
to clinicians and policymakers, to support developing AMS 
protocols for low resource settings. We will publish our 
results in peer- reviewed journals.
Trial registration number CRD42020210634.
INTRODUCTION
Infectious diseases are among the top leading 
causes of death worldwide and predominantly 
affect children in low and middle- income 
countries.1–5 A major challenge to managing 
infectious diseases in these settings is the 
growing resistance to current antimicrobials.6
A large surveillance study in Malawi found 
that antimicrobial resistance (AMR) to first- 
line antibiotics (amoxycillin, chloramphen-
icol and cotrimoxazole) increased between 
1998 and 2016.7 About 40% of all isolates 
were resistant to one or two first- line anti-
biotics.7 Among children aged less than 5 
years, resistance to first- line antibiotics from 
Gram- negative organisms rose from 3.4% to 
30.2% and from 5.9% to 93.7% for Klebsi-
ella species.6 Drug- resistant Gram- negative 
bacteria are particularly concerning as they 
are associated with increasing mortality in 
low- income countries.5 8 9
AMR complicates the management of 
common infectious diseases in these settings. 
For example, the majority of cases and deaths 
from bacterial meningitis occur in children 
from less developed countries.3 However 
AMR among antimicrobials used to treat 
Streptococcus pneumoniae, Haemophilus influenza 
or Neisseria meningitidis is found at presumed 
higher rates in low resource countries.3 10 
Other examples are diarrhoeal diseases that 
are the leading causes of death and disability 
in developing countries where enteric patho-
gens are found to be resistant to commonly 
prescribed antimicrobials.1 11 12 Among 
neonates, the rising exposure to prophylactic 
antibiotics in pregnant women and very low 
birth weight infants raises concerns about 
possible AMR- resistant neonatal sepsis, which 
could increase cases and deaths from Group 
B Streptococcus.2 8 13–15
Several factors contribute to AMR in devel-
oping countries. First, the lack of financial 
resources and expertise for blood culture and 
Strengths and limitations of this study
 ► This study will identify antimicrobial stewardship 
(AMS) practices in low- income and least developed 
countries.
 ► We will describe the outcomes and impact of identi-
fied AMS practices.
 ► Risk of bias will be assessed using the Integrated 
quality Criteria for Review of Multiple Study Designs.
 ► Expected limitations include the variation in out-
come measures, differences in the quality of the 
studies identified and publication bias.
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antimicrobial sensitivity analyses is a challenge to appro-
priate prescription and surveillance.8 10 11 13 Second, the 
use of prescription antibiotics is often unregulated and 
antibiotics can be obtained without prescriptions in many 
developing countries.8 13 16 In these settings, cheaper 
alternatives are used in place of effective antibiotics and 
result in AMR in hospitals and communities.13 This can 
cause changes in the pathogen profile of a population 
and perpetuate AMR.8 13 Third is the lack of appropriate 
policies to regulate prescribing practices, which means 
that efforts to mitigate the problem are uncoordinated 
and ineffective.8 16 Efforts to mitigate these challenges are 
important to prevent cases and deaths from infections 
attributable to AMR.
These efforts are antimicrobial stewardship (AMS) 
practices, which are coordinated interventions aimed 
at promoting appropriate prescription of antibi-
otics.17 18 Structural interventions involve new diagnostic 
tests, persuasive interventions target behavioural change 
in prescribing practices, enabling interventions educate 
prescribers and restrictive interventions involve regula-
tions for the usage of some antimicrobials.17 18 AMS strat-
egies can use these classes of interventions individually or 
in combination.17 18 Other measures have incorporated 
clean water and hygiene practices for infection preven-
tion.8 13 All AMS strategies use guidelines with defined 
recommendations measured as quality indicators for 
each intervention.16 18 19
The WHO recommends surveillance systems for AMR 
to detect bacterial infections, identify resistance patterns 
and monitor interventions.20 To do this, context- specific 
policies or protocols should be developed in order to 
guide acceptable and effective AMS solutions.16–18 21 
Although studies of different AMS practices have shown 
that they work to improve prescribing practices, there is 
little evidence to guide AMS in low resource settings.4 17 18
A review of AMS interventions in low and middle- 
income countries showed that most studies on AMS 
interventions report a positive effect for hospitalised 
patients.17 However, only two low- income countries were 
represented in this review and no recommendations 
could be made for AMS interventions because of the vari-
ation of strategies reviewed.17 Another review that studied 
the scope of AMS in children did not specifically identify 
interventions in low resource settings.22 There is a paucity 
of data to guide AMS interventions in low- income coun-
tries although they face the most risk of infectious disease 
and AMR.4
To address this, our systematic review aims to identify 
protocols, policies or procedures for AMS in hospital 
settings in least developed countries, defined by the 
Development Assistance Committee (DAC) criteria.23 
The aim of this systematic review is to answer the following 
research question: What are the interventions (protocols, 
policies or procedures) for antimicrobial stewardship for 
hospitalised patients of all ages in least developed and 
low- income countries? Second, we aim to describe the 
impact of antimicrobial stewardship interventions on 
prescribing practices, clinical outcomes and AMR in least 
developed and low- income countries.
METHODS
Protocol and registration
The systematic review protocol was registered PROS-
PERO, with the International Prospective Register of 
Systematic Reviews. It will be conducted according to 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) checklist.24 Amendments that 
may be made at any stage of the study will be reflected in 
amendments to the register.
Study design
We will review AMS interventions in DAC least and 
low- income settings. We expect significant variation in 
the types of interventions studied and, in the methods, 
populations studied. Therefore, given anticipated 
limited data, there may not be sufficient studies to 
conduct a meta- analysis of interventions and outcomes.
Eligibility criteria
Population
The population under study are neonates, children 
and adults in least developed and low- income countries 
as classified by DAC criteria.23 We will include studies 
about hospital- based AMS approaches including surgical 
patients. Trials on long- term patients and community- 
based patients will be excluded (table 1).
Intervention
The intervention of interest is all Antimicrobial stew-
ardship approaches, policies, practices or regulations in 
place to ensure judicious prescription of antimicrobials 
(table 1). We will include studies for which the interven-
tion is clearly applied to the specified population. Reviews 
of interventions will not be included.
Interventions will be described as structural, 
enabling, persuasive, restrictive or combined according 
to the Cochrane Interventions to improve antibiotic 
prescribing practices for hospital inpatients.25 Struc-
tural interventions include using digital records, rapid 
antimicrobial diagnostics or inflammatory markers 
to guide antimicrobial prescribing. Persuasive inter-
ventions include audits of prescription practices of 
healthcare workers and feedbacking information 
on where they can improve. Enabling interventions 
involve actively educating healthcare workers through 
treatment guidelines, training modules and reminders 
(posters or cards). Restrictive interventions involve 
authorising antimicrobial prescriptions, necessitating 
antibacterial sensitivity analyses or automatically 
discontinuing antimicrobial therapy for certain condi-
tions after a specified period. Combined or bundled 
interventions will be those that combine at least two 
types of these interventions.
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All interventions involving hygiene and sanitation will 
be described as infection prevention strategies. Studies 
with information on infection prevention will be included 
if they are incorporated as part of at least one type of AMS 
intervention described above.
Comparator
There is no comparator for this systematic review.
Outcome
The outcomes of interest will be categorised into 
behavioural, clinical and microbiological outcomes 
(table 1). Behavioural outcomes include changes in 
prescribing practices among medical personnel and 
compliance to AMS policies or protocols. Where available, 
a metric will be used to describe changes in prescribing 
practices, for example, daily doses per 100 bed- days.
Clinical outcomes include the following: treatment 
success will be defined as the successful eradication of a 
specified pathogen from an individual by microbiolog-
ical confirmation or by clinical improvement described 
by a study physician. Clinical outcomes will also include 
mortality or length of stay in hospital or duration of anti-
microbial use.
Microbiological outcomes include isolation of bacteria 
resistant to at least one antibiotic. It is expected that clin-
ical suspicion of bacterial infection is a major indication 
for antibiotic prescription in the population of interest. 
Therefore, we will describe bacterial infection as clin-
ical suspicion or confirmed microbiological infection. 
Confirmed microbiological infection will apply to studies 
that performed culture and or susceptibility testing. In 
this way, we intend to identify AMS protocols, which were 
applied for treatment of confirmed and suspected infec-
tions. Infection will apply to patients who had a bacterial 
infection as their primary illness or as a comorbidity of an 
underlying condition.
Information sources
The data sources include PubMed, Ovid Medline, Ovid 
EMBASE, WHO Library Database (WHOLIS), African 
Index Medicus (AIM) and Cochrane Central Register of 
Controlled Trials (CENTRAL). We will study bibliogra-
phies in studies found to create a comprehensive list of 
relevant studies that might have been missed during the 
initial database search. Where necessary, we will contact 
authors for supporting information.
Types of studies
We will include randomised controlled trials (RCT), 
before–after (CBA, controlled and non- controlled) inter-
rupted time series (ITS, controlled and non- controlled) 
and cohort studies. We will also include qualitative studies 
that describe interventions targeting behavioural change 
and other relevant AMS strategies.
Search strategy
Two independent reviewers will conduct literature search 
using the prespecified terms.
Population
Low- income country or least developed country and 
hospital or primary care or community hospital or district 
hospital or tertiary hospital or tertiary care and adults or 
children or neonates or obstetrics or women.
Intervention
Antimicrobial stewardship or antimicrobial stewardship 
protocols or rapid antimicrobial diagnostics or antimicro-
bial training.
Table 1 Systematic review inclusion and exclusion criteria
PICO Inclusion criteria Exclusion criteria
Population Studies on AMS, protocols or policies in DAC least developed and low- 
income countries
Hospitalised patients including surgical patients.
All age groups.
Studies on prescribers for hospitalised patients in DAC least developed 
countries
Trials on patients in the 
communities with no history of 
hospital admission during the 
period of the trial.
Patients classified by respective 
study to be in long- term care
Intervention Antimicrobial stewardship approaches, programmes, policies where AMS 
is the sole intervention or at least one element of an intervention; and/or 
interventions targeting hospital hygiene or infection transmission control 
strategies.
Studies on viral, fungal or parasite 
infections where bacterial infection 
data cannot be extracted.
Comparison None None
Outcomes Behavioural outcomes: changes in prescribing practices
Microbiological outcomes: bacterial infection confirmed by culture and 
sensitivity or by clinical suspicion. Confirmed microbiological infection with 
resistant bacteria at admission, during hospital stay or post discharge.
Clinical outcomes: treatment success (confirmed microbiological 
clearance or clinical improvement) length of stay in hospital or death.
Studies comparing the therapeutic 
effectiveness of one type of 
antimicrobial against another type. 
These are studies with the primary 
goal of determining superiority of 
one drug.
AMS, antimicrobial stewardship; DAC, Development Assistance Committee; PICO, Participants Intervention Comparison Outcomes.
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Outcome
Prescription practices or compliance or treatment success 
or mortality or length of hospital stay or AMR or first- 
line antibiotics or second- line antibiotics or multidrug- 
resistant bacterial infection.
During the review of titles and abstracts, reviewers will 
include publications on AMR and antimicrobial steward-
ship in the countries listed in the DAC criteria as least 
developed or low income. Studies will be excluded if 
they are about animal studies or are exclusively primarily 
about viral, fungal or parasite infections, with no impli-
cationsof, or data on bacterial infections that can be 
extracted. We will limit this systematic review to studies 
published in English. We will only include articles from 
studies between the year 2000 and 2020. The list of arti-
cles collected by the two reviewers will be consolidated 
and duplicates will be removed.
During the second phase of the review, full- text review 
and analysis will be done. Studies included will need to 
have occurred within the population of interest and the 
interventions need to be clearly applicable to specified 
settings.
A third reviewer will resolve discrepancies in selection 
and their decision will be final. Full- text review will be 
conducted for the selected literature.
Data extraction, synthesis and management
Data extraction will be done using the Cochrane collabo-
ration data collection form for intervention reviews.26 This 
form is a comprehensive assessment of full- text reviews. 
Qualitative data will be extracted through a form adapted 
from the Cochrane guidelines for extracting qualitative 
information.27 The reasons for exclusion at this stage will 
be recorded in these forms. The process of data selec-
tion leading up to data synthesis will be presented using 
the PRISMA flowchart.28 Due to the expected variation 
in methods and outcomes, a meta- analysis will not be 
performed.
Information will be categorised according to the demo-
graphic group, that is, neonates, children under 18, adults 
and obstetric patients. Due to the expected variation in 
methods and reporting practices, a narrative approach 
will be used to synthesise and report the data. Outcomes 
will be categorised according to the target of the interven-
tion. Emerging themes from the data will be presented. A 
data summary table will be created to demonstrate major 
themes and interventions from included studies.
Before beginning the systematic review, two authors 
will pilot the data extraction form independently for five 
full review papers. Discrepancies in data collection will be 
consolidated and the data collection form will be adapted 
to reflect all information required.
Assessment of risk of bias
This systematic review will be conducted according to the 
PRISMA guidelines.29
The assessment of risk of bias will be done according 
to the Integrated quality Criteria for Review of Multiple 
Study Designs (ICROMS).30 We expect that multiple 
study designs could be used to describe and assess AMS 
strategies in low resource settings. The ICROMS tool 
allows for a comprehensive assessment of the quality 
criteria for Randomized Controlled Trials, Interupted 
Time Series, Controlled Before- After, Non- Controlled 
Before- After cohort and qualitative studies.30 This 
allows for the inclusion of qualitative studies, which 
may assess behavioural change in prescribing practices 
as is important to AMS.
This tool assesses the quality of studies on the social 
and contextual determinants of an intervention and 
outcome. ICROMS was adopted for systematic reviews 
and meta- analysis in infection prevention and antimicro-
bial prescribing.30
Using the ICROMS tool, each study will be assessed 
for universally acceptable standards for its respec-
tive study type. This means randomised controlled 
studies will be assessed according to their own study 
type and standards and qualitative studies will also 
have their own criterion. Seven dimensions describe 
the quality criteria each study type will be assessed 
for. These are clear aims and justification, managing 
bias in sampling or between groups, managing bias in 
outcome measurements and blinding, managing bias 
in follow- up, managing bias in other study aspects, 
analytical rigour and managing bias in reporting/
ethical considerations. Each type of study will then be 
assessed on its quality criteria among 33 criteria.30
Using the ICROMS tool, methodological robustness of 
a study is analysed by assessing whether the study meets 
the prespecified mandatory criterion and its type of study. 
Studies that do not meet the mandatory criteria will be 
excluded.
The scientific validity of each study will be assessed by 
calculating a minimum score of criteria met within the 
quality dimensions.30 Each criterion met receives 2 points, 
if it is unclear whether the criteria is met, it is given 1 
point and no points are accorded for study criteria that 
are clearly not met. The total quality score for each study 
is compared with the minimum score of its study type. 
The minimum score for each type of study represents 
60% of the criteria required to demonstrate that the 
study was scientifically valid and that the outcomes are 
reliable.30 The minimum scores range from 22 points 
for RCT, cluster RCT, Non- Controlled Interrupted Time 
Series and Non- Controlled Before- After, 18 points for 
Controlled Before- After, Controlled Interrupted Time 
Series and cohort studies and 16 points for qualitative 
studies.30 Studies not meeting the minimum score will be 
excluded.
The adapted ICROMS template is shown in online 
supplemental appendix. This template includes a 
summary table for the risk of bias analysis of all studies. 
We will reference the detailed ICROMS protocol30 when 
deciding on the score for each criterion.
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Ethics and dissemination
We do not expect to use patient data for this review and 
will not require ethical clearance. We will use the results 
from this review to design candidate interventions for 
AMS practices that can be tested this low resource setting. 
Our AMS protocol design will involve meeting with rele-
vant Ministry of Health and Chikwawa Clinical officials 
to discuss which elements of our findings can be incor-
porated into an AMS strategy. This review will specifically 
inform the development of AMS practices and policies 
to be tested by the Paediatric Research in Antimicrobial 
Stewardship and Management network in Chikwawa 
district in Malawi. Malawi is a southern- African country 
classified as a DAC least developed country, and the inci-
dence of AMR is rising.23 31 Finding ways to promote AMS 
in this setting can be useful for similar settings as well. 
We will publish findings from this review in peer- reviewed 
journals and present our research to local and interna-
tional conferences.
Twitter Grace Wezi Mzumara @gracemzumara16
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